<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-108489</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Factors Associated with the Evolution of Lung Function in Patients With Alpha-1 Antitrypsin Deficiency in the Spanish Registry</dc:title>
<dc:description xml:lang="en">Introduction: The present study intends to describe the characteristics of patients diagnosed with severe alpha-1 antitrypsin deficiency (AATD) in Spain, to observe the rate of decline in forced expiratory volume in 1 second (FEV1) with and without substitutive therapy, and to identify factors associated with a rapid rate of decline in FEV1. Method: A retrospective study of the evolution of individuals with AATD was carried out based on data collected from the Spanish registry. The primary response variable was the annual rate of decline in FEV1, calculated using the baseline and last postbronchodilator FEV1 values in an endpoint analysis. Results: 303 patients with severe AATD and Pi ZZ phenotype were identified. Follow-up spirometric data were collected for 117 subjects. Being a smoker or ex-smoker versus never smoker (odds ratio [OR]=10.31; 95% confidence interval (CI)=1.8-58.8; p=0.008) and having a higher baseline postbronchodilator FEV1 (% predicted) (OR=1.03; 95% CI=1.005-1.06; p=0.018) were independently associated with a more rapid rate of decline in FEV1. There was also a trend towards a relationship between low body mass index (BMI) and a greater rate of deterioration in lung function (OR=1.14; 95% CI=0.98-1.33; p=0.085). Conclusion: Being a smoker or ex-smoker, greater baseline lung function, and low BMI were the main risk factors associated with an accelerated rate of decline in FEV1. This finding warrants the close observation of younger patients with a better-preserved FEV1(AU)</dc:description>
<dc:creator>Cadenas, Sergio</dc:creator>
<dc:creator>Lázaro, Lourdes</dc:creator>
<dc:creator>Tirado-Conde, Gema</dc:creator>
<dc:creator>Blanco, Ignacio</dc:creator>
<dc:creator>Casas, Francisco</dc:creator>
<dc:creator>Martínez, María Teresa</dc:creator>
<dc:creator>Vidal, Rafael</dc:creator>
<dc:creator>Torres, María</dc:creator>
<dc:creator>Miravitlles, Marc</dc:creator>
<dc:creator>Lara, Beatriz</dc:creator>
<dc:creator>Hernández Pérez, José María</dc:creator>
<dc:creator>Bustamante, Ana</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: El presente estudio pretende describir las características de los pacientes diagnosticados de déficit grave de alfa-1-antitripsina (AAT) en España, calcular la tasa de descenso del FEV1 con y sin tratamiento sustitutivo, e identificar factores asociados a una tasa de descenso acelerada del FEV1.Método: Estudio retrospectivo de la evolución de los individuos con déficit de alfa-1-antitripsina (DAAT) incluidos en el registro español. La variable principal evaluada en el estudio fue la tasa anual de descenso del FEV1.Resultados: Se identificaron 303 pacientes con DAAT grave y fenotipo Pi ZZ. Se dispuso del seguimiento espirométrico de 117 pacientes. Ser fumador activo o ex fumador frente a nunca fumador (odds ratio [OR]=10,31; intervalo de confianza (IC) del 95%=1,8-58,8; p=0,008) y tener un mayor FEV1(%) posbroncodilatador (OR=1,03; IC del 95%=1,005-1,06; p=0,018), se asociaron de manera independiente a una tasa más acelerada de descenso del FEV1. Se apreció una tendencia entre tener un índice de masa corporal (IMC) bajo y experimentar una mayor tasa de deterioro del FEV1 (OR=1,14; IC del 95%=0,98-1,33; p=0,085). Conclusiones: Ser fumador o ex fumador, tener una función pulmonar preservada y un bajo IMC fueron los principales factores de riesgo asociados a una tasa acelerada de descenso del FEV1. Este hallazgo justificaría la necesidad de efectuar un seguimiento estrecho de los pacientes jóvenes con un FEV1 más preservado(AU)</dc:description>
<dc:source>Arch Bronconeumol;47(10): 495-503, oct. 2011. tab</dc:source>
<dc:identifier>ibc-108489</dc:identifier>
<dc:title xml:lang="es">Factores asociados a la evolución de la función pulmonar en pacientes con déficit de alfa-1-antitripsina del registro español</dc:title>
<dc:subject>^d5703^s22045</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d27940^s22073</dc:subject>
<dc:subject>^d33363^s22016</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23925^s22080</dc:subject>
<dc:subject>^d33363^s22067</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d13530^s22074</dc:subject>
<dc:subject>^d14417^s22020</dc:subject>
<dc:subject>^d28628^s22066</dc:subject>
<dc:subject>^d33363</dc:subject>
<dc:type>article</dc:type>
<dc:date>201110</dc:date>
</metadata>
</record>
</ibecs-document>
